Talking Euretina
A podcast by Whipsmart Media

Categories:
60 Episodes
-
Episode 39: The Euretina Retinal Medicine Clinical Research Award
Published: 15/11/2023 -
Episode 38: Preview of Euretina Congress 2023
Published: 29/09/2023 -
Episode 37: Blind Faith - How RP patients are being targeted with bad science across the world
Published: 15/09/2023 -
Episode 36: The Ophthalmologica Lecture: Maximilian Pfau
Published: 1/09/2023 -
Episode 35: Treating PCV and Pachychoroid in Different Populations
Published: 15/08/2023 -
Episode 34: The Euretina Lecture: OncoVR
Published: 31/07/2023 -
Episode 33: The Euretina Innovation Summit - All You Need to Know
Published: 3/07/2023 -
Episode 32: Macular Holes and Glaucoma in Myopia
Published: 15/06/2023 -
Episode 31: Featured studies from the Ophthalmologica journal
Published: 18/05/2023 -
Episode 30: Intraocular Lymphoma: An Explainer
Published: 2/05/2023 -
Episode 29: How to get published in Euretina’s Journal, Ophthalmologica
Published: 14/04/2023 -
Episode 28: Diabetic Retinopathy - the latest exciting developments from across the world
Published: 30/03/2023 -
Episode 27: What do we mean by ”macula-off” RRD ... and how soon should we act?
Published: 14/03/2023 -
Episode 26: Tackling Acute Retinal Necrosis in Patients
Published: 1/03/2023 -
Episode 25: What individual patient data can tell us about treating macular holes
Published: 15/02/2023 -
Episode 24: Five Years after Approval of Voretigene Neparvovec – What is The Future of Retinal Gene Therapy?
Published: 6/02/2023 -
Episode 23: Everything You Need to Know About the New EBO-Euretina Exam
Published: 17/01/2023 -
Episode 22: Women in Retina
Published: 1/12/2022 -
Episode 21: What To Know About The Bad Guy In Myopia: Staphyloma
Published: 17/11/2022 -
Episode 20: A Deep Dive into the MOLES System
Published: 3/11/2022
Expert Discussions from the World of Retina: Exploring the latest developments in the field with world-renowned leaders. It will feature a monthly subspecialty journal club, panel discussions and interviews with key opinion leaders.